{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T22:03:52Z","timestamp":1793829832587,"version":"4.6.1"},"reference-count":30,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T00:00:00Z","timestamp":1751241600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T00:00:00Z","timestamp":1751241600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ther Adv Neurol Disord"],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Changes in the original protocol of clinical trials should be clearly declared to the readers of journal publications. Otherwise, they can lead to selective outcome reporting bias or distort the appropriate judgement of the study\u2019s external validity and statistical power, among other problems.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>To identify silent protocol modifications in phase III and IV clinical trials examining multiple sclerosis (MS) drugs that have been carried out between 2010 and mid-2023.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design:<\/jats:title>\n                    <jats:p>Comparative analysis of ClinicalTrials.gov and associated peer-reviewed journal publications.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>An advanced search in ClinicalTrials.gov was performed and consecutive searches in PubMed, EMBASE and Google Scholar were conducted looking for the main journal publication derived from each trial. Information regarding trial design, eligibility criteria, primary outcomes and sample size estimation was simultaneously collected from ClinicalTrials.gov and publications, and subsequently compared.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>In total, 112 trials were appraised. Most studies matched between data sources in terms of study arms (96.4%), assignment (99.1%) and randomization (100.0%). Concordance was also high but comparatively lower for masking (82.1%). A total of 3051 eligibility criteria were extracted, 45.5% of which matched, 25.1% were omitted in publications, 2.8% were modified and 26.6% were added. Fifty-eight trials (51.8%) completely matched regarding their published primary outcomes, whereas 20 had major inconsistencies (17.9%) and 34 (30.4%) minor inconsistencies. Fourteen trials were inconsistent in their estimated sample size; among these, the median difference between registry and publications was 36.5 individuals (interquartile range 17\u2013161). The proportion of trials exhibiting silent protocol changes was similar regardless of study phase, industry involvement or type of registration.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Silent protocol changes are common in MS clinical trials and potentially hinder the interpretation and applicability of results. Efforts must be made to promote more transparency in the field of MS clinical research.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/17562864251335247","type":"journal-article","created":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T07:57:36Z","timestamp":1751270256000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":3,"title":["Silent protocol modifications in multiple sclerosis clinical trials: a registry-based cross-sectional study"],"prefix":"10.1177","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1818-8622","authenticated-orcid":false,"given":"Alejandro","family":"Rivero-de-Aguilar","sequence":"first","affiliation":[{"name":"Department of Neurology, University Hospital Complex of Pontevedra, Pontevedra, Spain"},{"name":"Department of Epidemiology and Public Health, University of Santiago de Compostela, Santiago de Compostela, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00f3nica","family":"P\u00e9rez-R\u00edos","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Public Health, University of Santiago de Compostela, R\u00faa San Francisco, s\/n. 15782, Santiago de Compostela (A Coru\u00f1a), Spain"},{"name":"Health Research Institute of Santiago de Compostela (Instituto de Investigaci\u00f3n Sanitaria de Santiago de Compostela), Santiago de Compostela, Spain"},{"name":"Consortium for Biomedical Research in Epidemiology and Public Health (CIBER en Epidemiolog\u00eda y Salud P\u00fablica), Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph S.","family":"Ross","sequence":"additional","affiliation":[{"name":"Center for Outcomes Research and Evaluation, Yale New Haven Hospital, New Haven, CT, USA"},{"name":"Section of General Internal Medicine, Yale School of Medicine, New Haven, CT, USA"},{"name":"Department of Health Policy and Management, Yale School of Public Health, New Haven, CT, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Mascare\u00f1as-Garc\u00eda","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Public Health, University of Santiago de Compostela, Santiago de Compostela, Spain"},{"name":"Department of Preventive Medicine, University Hospital Complex of Santiago de Compostela, Santiago de Compostela, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Ruano-Ravi\u00f1a","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Public Health, University of Santiago de Compostela, Santiago de Compostela, Spain"},{"name":"Health Research Institute of Santiago de Compostela (Instituto de Investigaci\u00f3n Sanitaria de Santiago de Compostela), Santiago de Compostela, Spain"},{"name":"Consortium for Biomedical Research in Epidemiology and Public Health (CIBER en Epidemiolog\u00eda y Salud P\u00fablica), Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marilina","family":"Puente-Hernandez","sequence":"additional","affiliation":[{"name":"Department of Neurology, R\u00edo Carri\u00f3n General Hospital, Palencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonor","family":"Varela-Lema","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Public Health, University of Santiago de Compostela, Santiago de Compostela, Spain"},{"name":"Health Research Institute of Santiago de Compostela (Instituto de Investigaci\u00f3n Sanitaria de Santiago de Compostela), Santiago de Compostela, Spain"},{"name":"Consortium for Biomedical Research in Epidemiology and Public Health (CIBER en Epidemiolog\u00eda y Salud P\u00fablica), Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,6,30]]},"reference":[{"key":"e_1_3_5_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)31592-6"},{"issue":"20","key":"e_1_3_5_3_2","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects","volume":"310","author":"World Medical Association (WMA)","year":"2013","unstructured":"World Medical Association (WMA). World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA 2013; 310(20): 2191.","journal-title":"JAMA"},{"issue":"2","key":"e_1_3_5_4_2","first-page":"117","article-title":"Peer review: publication\u2019s gold standard","volume":"3","author":"Mayden KD.","year":"2012","unstructured":"Mayden KD. Peer review: publication\u2019s gold standard. J Adv Pract Oncol 2012; 3(2): 117\u2013122.","journal-title":"J Adv Pract Oncol"},{"issue":"1","key":"e_1_3_5_5_2","article-title":"Comparison of protocols and registry entries to published reports for randomised controlled trials","volume":"2011","author":"Dwan K","year":"2011","unstructured":"Dwan K, Altman DG, Cresswell L, et al. Comparison of protocols and registry entries to published reports for randomised controlled trials. Cochrane Database Syst Rev 2011; 2011(1): MR000031.","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_5_6_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjebm-2018-111107"},{"key":"e_1_3_5_7_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.291.20.2457"},{"key":"e_1_3_5_8_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d1828"},{"key":"e_1_3_5_9_2","unstructured":"U.S. Food & Drug Administration. Food and Drug Administration Amendments Act of 2007. Public Law 110-85 US Public Law 110\u201385. Washington (District of Columbia): Food and Drug Administration 2007 pp. 1\u2013156."},{"key":"e_1_3_5_10_2","unstructured":"International Committee of Medical Journal Editors (ICMJE). Clinical trials registration [Internet] https:\/\/www.icmje.org\/about-icmje\/faqs\/clinical-trials-registration (accessed 1 January 2025)"},{"key":"e_1_3_5_11_2","unstructured":"World Association of Medical Editors (WAME). WAME Editorial Policy Committe. The registration of clinical trials. [Internet] https:\/\/wame.org\/registration-clinical-trials (accessed 1 January 2025)"},{"key":"e_1_3_5_12_2","unstructured":"ClinicalTrials.gov. Trends and charts on registered studies [Internet] https:\/\/clinicaltrials.gov\/about-site\/trends-charts (accessed 14 March 2025)."},{"key":"e_1_3_5_13_2","doi-asserted-by":"crossref","unstructured":"Zarin DA Fain KM Dobbins HD et al. 10-year update on study results submitted to ClinicalTrials.gov. N Engl J Med 2019; 381(20): 1966\u20131974.","DOI":"10.1056\/NEJMsr1907644"},{"key":"e_1_3_5_14_2","doi-asserted-by":"publisher","DOI":"10.1097\/SLA.0b013e3182864fa3"},{"key":"e_1_3_5_15_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw682"},{"key":"e_1_3_5_16_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0178379"},{"key":"e_1_3_5_17_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-016-1551-6"},{"key":"e_1_3_5_18_2","doi-asserted-by":"publisher","DOI":"10.1093\/ejo\/cjy046"},{"key":"e_1_3_5_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01473-3"},{"key":"e_1_3_5_20_2","doi-asserted-by":"crossref","unstructured":"Rivero-de-Aguilar A P\u00e9rez-R\u00edos M Ruano-Ravi\u00f1a A et al. Evidence of publication bias in multiple sclerosis clinical trials: a comparative analysis of published and unpublished studies registered in ClinicalTrials.gov. J Neurol Neurosurg Psychiatry 2023; 94(8): 597\u2013604.","DOI":"10.1136\/jnnp-2023-331132"},{"key":"e_1_3_5_21_2","unstructured":"Food and Drug Administration. Drugs@FDA [Internet] https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm (accessed 11 March 2025)."},{"key":"e_1_3_5_22_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2009.1242"},{"key":"e_1_3_5_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2009.04.003"},{"key":"e_1_3_5_24_2","doi-asserted-by":"publisher","DOI":"10.1097\/EDE.0000000000000564"},{"key":"e_1_3_5_25_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.c332"},{"key":"e_1_3_5_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2022.104422"},{"key":"e_1_3_5_27_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000208032"},{"key":"e_1_3_5_28_2","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne JAC","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 2019; 366: l4898.","journal-title":"BMJ"},{"key":"e_1_3_5_29_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMsa1012065"},{"key":"e_1_3_5_30_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djw129"},{"key":"e_1_3_5_31_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0127495"}],"container-title":["Therapeutic Advances in Neurological Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17562864251335247","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/17562864251335247","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17562864251335247","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T05:05:38Z","timestamp":1767675938000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/17562864251335247"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,30]]},"references-count":30,"alternative-id":["10.1177\/17562864251335247"],"URL":"https:\/\/doi.org\/10.1177\/17562864251335247","relation":{},"ISSN":["1756-2864","1756-2864"],"issn-type":[{"value":"1756-2864","type":"print"},{"value":"1756-2864","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,30]]},"article-number":"17562864251335247"}}